Endologix, Inc. (NASDAQ:ELGX) – Oppenheimer Holdings raised their FY2017 earnings per share estimates for shares of Endologix in a research note issued to investors on Wednesday. Oppenheimer Holdings analyst S. Lichtman now expects that the medical instruments supplier will post earnings of ($0.56) per share for the year, up from their previous forecast of ($0.60). Oppenheimer Holdings currently has a “Hold” rating and a $5.00 price objective on the stock. Oppenheimer Holdings also issued estimates for Endologix’s Q4 2017 earnings at ($0.17) EPS and FY2018 earnings at ($0.48) EPS.

TRADEMARK VIOLATION NOTICE: “FY2017 Earnings Estimate for Endologix, Inc. Issued By Oppenheimer Holdings (ELGX)” was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.watchlistnews.com/fy2017-earnings-estimate-for-endologix-inc-issued-by-oppenheimer-holdings-elgx/1697066.html.

Several other research firms have also weighed in on ELGX. Royal Bank of Canada reaffirmed a “hold” rating and set a $5.00 price target on shares of Endologix in a research report on Monday, July 31st. Canaccord Genuity reissued a “hold” rating on shares of Endologix in a report on Friday, August 4th. BidaskClub lowered Endologix from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Zacks Investment Research lowered Endologix from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 25th. Finally, Stifel Nicolaus set a $6.00 target price on Endologix and gave the stock a “hold” rating in a report on Wednesday, August 2nd. Two analysts have rated the stock with a sell rating and eleven have assigned a hold rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $6.13.

Endologix (ELGX) opened at $5.06 on Friday. Endologix has a 1 year low of $4.08 and a 1 year high of $10.36. The company has a current ratio of 2.90, a quick ratio of 2.12 and a debt-to-equity ratio of 2.61.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Kopp Investment Advisors LLC boosted its stake in Endologix by 11.5% in the 2nd quarter. Kopp Investment Advisors LLC now owns 21,950 shares of the medical instruments supplier’s stock valued at $107,000 after purchasing an additional 2,270 shares during the period. Verition Fund Management LLC bought a new stake in Endologix in the 2nd quarter valued at $111,000. Dynamic Technology Lab Private Ltd bought a new stake in Endologix in the 2nd quarter valued at $142,000. UBS Asset Management Americas Inc. boosted its stake in Endologix by 128.1% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 34,898 shares of the medical instruments supplier’s stock valued at $170,000 after purchasing an additional 19,600 shares during the period. Finally, Voya Investment Management LLC boosted its stake in Endologix by 16.4% in the 2nd quarter. Voya Investment Management LLC now owns 38,910 shares of the medical instruments supplier’s stock valued at $189,000 after purchasing an additional 5,471 shares during the period.

About Endologix

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Earnings History and Estimates for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.